Sairopa Presents Early Clinical Data on ADU-1604 Compound at SITC 38th Annual Meeting

ROTTERDAM, The Netherlands – November 4, 2023 – sairopa.com – a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system, presented early clinical data on ADU-1604, its proprietary anti-CTLA4 antibody at the SITC 38th Annual Meeting. Data obtained from the ongoing Phase 1 dose-escalation stage in PD1 relapse/refractory melanoma patients (N=17) were presented. ADU-1604 is well tolerated at the dosages tested (25, 75, 225 and 450 mg Q3W). No dose-limiting toxicities or treatment-related severe adverse events have been reported up to now. Pre-clinical data was presented that potentially explains the suggested improved safety profile of ADU-1604 vs. other anti-CTLA4 antibodies. ADU-1604 was shown to dose-dependently increase pharmacodynamic biomarkers, which correlates with early signs of clinical activity. Finally, early clinical efficacy data was reported showing one unusually long stable disease and two ongoing tumor regressions.